Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Positron Emission Tomagraphy (PET) Study Following a Single Oral Dose of OPC-34712

This study has been completed.
Otsuka Pharmaceutical Co., Ltd.
Information provided by:
Otsuka Pharmaceutical Development & Commercialization, Inc. Identifier:
First received: December 4, 2008
Last updated: May 6, 2010
Last verified: May 2010
Determine the degree of striatal D2 receptor occupancy induced by OPC-34712 at differenht dose levels in healthy volunteers.

Condition Intervention Phase
Drug: OPC-34712
Phase 1

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Basic Science
Official Title: A Phase I, Open-Label,Positron Emission Tomography (PET) Study Healthy Subjects Following a Single Oral Dose of OPC-34712

Resource links provided by NLM:

Further study details as provided by Otsuka Pharmaceutical Development & Commercialization, Inc.:

Primary Outcome Measures:
  • Pharmacodynamic: Percent occupancy of D2 receptor, as judged by PET scan. [ Time Frame: 10 days ]

Secondary Outcome Measures:
  • Measure safety: adverse events, vital signs, ECGs, and clinical laboratory tests [ Time Frame: 30 days ]

Enrollment: 15
Study Start Date: December 2008
Study Completion Date: July 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: OPC-34712
    Single oral dose, 0.5 to 25 mg
Detailed Description:
Subjects will receive a dose of study medication and will undergo a PET scan at 4 hrs and 23.5 hours post dose. Subjects will remain in the clinic from Day-1 to Day 7 for PK sample collection and safety monitoring. Subjects will return to the clinic on Day 10 for a follow-up safety assessment.

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Males and non-child bearing potential females between 18 and 45 years of age, inclusive.
  • BMI between 19 and 32 kg/m2, inclusive.

Exclusion Criteria:

  • Condition or history which may present a safety concern to the subject or interfere with outcome variables.
  • History of or current drug or alcohol abuse, hepatitis, AIDS, or drug allergy.
  • Use of prescription, over-the-counter, or herbal medication, or vitamin supplements within 14 days or antibiotics within 30 days.
  • Use of tobacco products or daily exposue to second hand smoke.
  • Blood pressure higher than 140/90 mmHg or lower than 100/50 mmHg: heart rate outside 40 to 90 beats/minute.
  • History of serious mental disorder.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00805454

Sponsors and Collaborators
Otsuka Pharmaceutical Development & Commercialization, Inc.
Otsuka Pharmaceutical Co., Ltd.
Principal Investigator: Dean Wong, MD,PhD Johns Hopkins University, Baltimore,MD 21287
Principal Investigator: Stephen Bart, MD SNBL, Baltimore,MD 21201
  More Information

Responsible Party: Patricia Bricmont, PhD, Associate Director Clinical Pharmacology, Otsuka Pharmaceutical Development & Commercialization, Inc. Identifier: NCT00805454     History of Changes
Other Study ID Numbers: 331-07-202
Study First Received: December 4, 2008
Last Updated: May 6, 2010

Keywords provided by Otsuka Pharmaceutical Development & Commercialization, Inc.:
Healthy Volunteers
Phase I
Pet Scan

Additional relevant MeSH terms:
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders processed this record on May 25, 2017